Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the value of negative trials, considering the slow progression in treating ovarian cancer.

He considers statistically positive studies that have limited benefit for patient survivals, trials finding improved progression-free survival but which fail for not meeting other primary endpoints, and the central importance of patient benefit in trial design.

Read Dr Gyawali’s article "Negative trials in ovarian cancer: is there such a thing as too much optimism?" here.

Dr Gyawali spoke further with ecancer about the balancing of risk and overall survival for patients treated with sorafenib, and contributes a regular blog with his views on recent research.